KOA SHOJI HOLDINGS CO.,LTD. Logo

KOA SHOJI HOLDINGS CO.,LTD.

Imports, sells, and manufactures APIs and intermediates for the pharmaceutical industry.

9273 | T

Overview

Corporate Details

ISIN(s):
JP3283420002
LEI:
Country:
Japan
Address:
横浜市港北区日吉七丁目13−15

Description

KOA SHOJI HOLDINGS CO.,LTD. is a holding company operating primarily in the pharmaceutical sector. Through its subsidiaries, the company specializes in the import, sale, and manufacturing of Active Pharmaceutical Ingredients (APIs) and intermediates. It is a key supplier to the generic pharmaceuticals market. In addition to its core business of supplying raw materials, the group also engages in the development and sale of its own pharmaceutical products and provides contract manufacturing services to other pharmaceutical companies. The company focuses on supporting the pharmaceutical industry from the upstream stages of the supply chain.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2021-03-04 08:50
訂正有価証券報告書-第6期(令和1年7月1日-令和2年6月30日)
Japanese 540.2 KB
2021-02-12 07:16
四半期報告書-第7期第2四半期(令和2年10月1日-令和2年12月31日)
Japanese 187.5 KB
2020-11-13 07:11
四半期報告書-第7期第1四半期(令和2年7月1日-令和2年9月30日)
Japanese 156.7 KB
2020-09-28 08:59
確認書
Japanese 8.1 KB
2020-09-28 08:58
内部統制報告書-第6期(令和1年7月1日-令和2年6月30日)
Japanese 22.7 KB
2020-09-28 08:57
有価証券報告書-第6期(令和1年7月1日-令和2年6月30日)
Japanese 878.7 KB
2020-05-13 08:01
四半期報告書-第6期第3四半期(令和2年1月1日-令和2年3月31日)
Japanese 153.3 KB
2020-02-13 07:31
四半期報告書-第6期第2四半期(令和1年7月1日-令和1年12月31日)
Japanese 178.6 KB
2019-11-11 07:32
四半期報告書-第6期第1四半期(2019/07/01-2019/09/30)
Japanese 146.2 KB
2019-09-27 08:32
有価証券報告書-第5期(平成30年7月1日-令和1年6月30日)
Japanese 867.8 KB
2019-05-13 08:33
四半期報告書-第5期第3四半期(2019/01/01-2019/03/31)
Japanese 149.0 KB
2019-02-12 08:02
四半期報告書-第5期第2四半期(2018/10/01-2018/12/31)
Japanese 161.6 KB
2018-11-12 07:23
四半期報告書-第5期第1四半期(2018/07/01-2018/09/30)
Japanese 138.8 KB
2018-09-27 08:22
有価証券報告書-第4期(平成29年7月1日-平成30年6月30日)
Japanese 828.8 KB

Automate Your Workflow. Get a real-time feed of all KOA SHOJI HOLDINGS CO.,LTD. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for KOA SHOJI HOLDINGS CO.,LTD.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for KOA SHOJI HOLDINGS CO.,LTD. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

4BASEBIO PLC Logo
Manufactures GMP-grade synthetic DNA for next-generation therapeutics and vaccines.
United Kingdom
4BB
4D Molecular Therapeutics, Inc. Logo
Develops genetic medicines using AAV vectors for ophthalmology and pulmonology diseases.
United States of America
FDMT
4SC AG Logo
Biopharmaceutical company with no products under development or operational business.
Germany
VSC
60 DEGREES PHARMACEUTICALS, INC. Logo
Develops and commercializes medicines for infectious diseases, focusing on tropical illnesses.
United States of America
SXTP
89bio, Inc. Logo
Clinical-stage biopharma developing therapies for liver and cardiometabolic diseases.
United States of America
ETNB
Aardvark Therapeutics, Inc. Logo
Clinical-stage biopharma developing therapeutics for hunger and metabolic diseases.
United States of America
AARD
ABBOTT LABORATORIES Logo
Global healthcare company in medical devices, diagnostics, nutrition & pharmaceuticals.
United States of America
ABT
AbbVie Inc. Logo
A research-based biopharmaceutical company developing and manufacturing medicines.
United States of America
ABBV
AbCellera Biologics Inc. Logo
Discovers and develops antibody-based therapeutics using a proprietary platform.
United States of America
ABCL
Develops antibody-based therapeutics using CAR-T, NEST, and AffiMab platforms.
South Korea
174900

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.